Internal Medicine, Medical Oncology · Hackensack, NJ
NPI
1609835586
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
92 2nd St
Hackensack, NJ, 07601
Phone (551) 996-5864
Groups this clinician bills Medicare through
Medicare paid, 2024
$339K
30,950 services
Medicare patients, 2024
784
Average age 74
Drug cost, 2024
$2.0M
1,530 prescriptions
Company payments, 2025
$345
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Stanley E Waintraub was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 1,568 times for 665 patients. In total Stanley E Waintraub billed 30,950 services in 19 codes, and Medicare paid $339K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-26.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,568 | 665 | $13.73 | $22K |
| 99214 Office E&M - Established | Office | 1,217 | 422 | $103.87 | $126K |
| Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 540 | 18 | $107.76 | $58K |
| 99215 Office E&M - Established | Office | 375 | 197 | $150.04 | $56K |
| 99213 Office E&M - Established | Office | 348 | 243 | $73.13 | $25K |
| Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 264 | 11 | $108.64 | $29K |
| 96372 Injection Administration | Office | 130 | 35 | $12.31 | $1,601 |
| 99232 Hospital E&M - Subsequent | Facility | 46 | 30 | $66.65 | $3,066 |
| 99205 Office E&M - New | Office | 34 | 34 | $185.14 | $6,295 |
By year: 2022 $317K for 14,930 services; 2023 $303K for 11,168 services; 2024 $339K for 30,950 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,570 | 580 | $7.41 | $12K |
| 85027 Blood Count | 73 | 54 | $6.11 | $446 |
Medicare prescription drug claims, 2024
In 2024, the drug Stanley E Waintraub prescribed most often to Medicare patients was Anastrozole, with 716 prescriptions and refills. In total Stanley E Waintraub wrote 1,530 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 716 | 2,076 | 228 | $15K |
| Exemestane Generic | 231 | 626 | 69 | $34K |
| Letrozole Generic | 124 | 340 | 40 | $2,750 |
| Ibrance Palbociclib | 70 | 70 | Under 11 | $1.1M |
| Verzenio Abemaciclib | 48 | 48 | Under 11 | $622K |
| Eliquis Apixaban | 31 | 43 | Under 11 | $25K |
| Prochlorperazine Maleate Generic | 26 | 26 | 11 | $290 |
| Arimidex Anastrozole | 25 | 39 | Under 11 | $60K |
| Warfarin Sodium Generic | 21 | 21 | Under 11 | $131 |
| Levothyroxine Sodium Generic | 20 | 34 | Under 11 | $170 |
| Raloxifene Hcl Generic | 15 | 40 | Under 11 | $927 |
| Erlotinib Hcl Generic | 13 | 13 | Under 11 | $2,054 |
| Ondansetron Hcl Generic | 12 | 12 | Under 11 | $77.74 |
| Gabapentin Generic | 11 | 21 | Under 11 | $258 |
| Tamoxifen Citrate Generic | 11 | 33 | Under 11 | $271 |
Brand drugs: - claims; generic drugs: 1,251 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Stanley E Waintraub $345 ($345 in general payments such as food, travel and fees) from 7 companies. The largest payer was Gilead Sciences, Inc. with $159.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.